|
OSBP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.16630047233934E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.91479995695454E-09 |
| Normal-vs-Stage2 |
4.581100E-04 |
| Normal-vs-Stage3 |
2.15050199869893E-11 |
| Normal-vs-Stage4 |
9.70040048287046E-10 |
| Stage1-vs-Stage2 |
2.439400E-01 |
| Stage1-vs-Stage3 |
9.161700E-02 |
| Stage1-vs-Stage4 |
8.988200E-02 |
| Stage2-vs-Stage3 |
2.116100E-02 |
| Stage2-vs-Stage4 |
1.823510E-02 |
| Stage3-vs-Stage4 |
6.655200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.08530978543331E-12 |
| Normal-vs-AfricanAmerican |
9.183300E-04 |
| Normal-vs-Asian |
4.65990000031447E-07 |
| Caucasian-vs-AfricanAmerican |
3.345800E-01 |
| Caucasian-vs-Asian |
8.329600E-01 |
| AfricanAmerican-vs-Asian |
4.699800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.36879976639659E-10 |
| Normal-vs-Female |
1.90240045938594E-10 |
| Male-vs-Female |
1.749960E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.06449999504844E-08 |
| Normal-vs-Age(41-60Yrs) |
1.14609988166592E-10 |
| Normal-vs-Age(61-80Yrs) |
2.95939994732208E-09 |
| Normal-vs-Age(81-100Yrs) |
5.375600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.025000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.358600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.852600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.058400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.097600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.320800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.955700E-03 |
| Classical-VS-Follicular |
8.674200E-01 |
| Classical-VS-Other |
1.501200E-01 |
| Classical-VS-Normal |
5.16160003627419E-10 |
| Tall-VS-Follicular |
2.671800E-02 |
| Tall-VS-Other |
6.303000E-01 |
| Tall-VS-Normal |
5.41509947993291E-10 |
| Follicular-VS-Other |
2.218000E-01 |
| Follicular-VS-Normal |
1.52773999999578E-05 |
| Other-VS-Normal |
5.976200E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.81679998717743E-09 |
| Normal-vs-N1 |
8.36489988387257E-10 |
| N0-vs-N1 |
6.422300E-02 |
|
|
